419 related articles for article (PubMed ID: 29857542)
41. Antibody recognition of fluorinated MUC1 glycopeptide antigens.
Oberbillig T; Mersch C; Wagner S; Hoffmann-Röder A
Chem Commun (Camb); 2012 Feb; 48(10):1487-9. PubMed ID: 21986937
[TBL] [Abstract][Full Text] [Related]
42. Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.
Seko A; Ohkura T; Ideo H; Yamashita K
Glycobiology; 2012 Feb; 22(2):181-95. PubMed ID: 21880669
[TBL] [Abstract][Full Text] [Related]
43. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten AA; Snijdewint FG; van Kamp GJ; Schol DJ; Reis CA; Price MR; Livingston PO; Hilgers J
Int J Cancer; 2000 Jun; 86(5):702-12. PubMed ID: 10797294
[TBL] [Abstract][Full Text] [Related]
44. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
45. Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues.
Wagner S; Mersch C; Hoffmann-Röder A
Chemistry; 2010 Jun; 16(24):7319-30. PubMed ID: 20461825
[TBL] [Abstract][Full Text] [Related]
46. Design of α-S-Neoglycopeptides Derived from MUC1 with a Flexible and Solvent-Exposed Sugar Moiety.
Rojas-Ocáriz V; Compañón I; Aydillo C; Castro-Loṕez J; Jiménez-Barbero J; Hurtado-Guerrero R; Avenoza A; Zurbano MM; Peregrina JM; Busto JH; Corzana F
J Org Chem; 2016 Jul; 81(14):5929-41. PubMed ID: 27305427
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
48. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells.
Persson J; Bäckström M; Johansson H; Jirström K; Hansson GC; Ohlin M
Tumour Biol; 2009; 30(4):221-31. PubMed ID: 19776674
[TBL] [Abstract][Full Text] [Related]
49. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
50. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
51. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.
Hanisch FG; Schwientek T; Von Bergwelt-Baildon MS; Schultze JL; Finn O
Eur J Immunol; 2003 Dec; 33(12):3242-54. PubMed ID: 14635032
[TBL] [Abstract][Full Text] [Related]
52. Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody.
Martínez-Sáez N; Castro-López J; Valero-González J; Madariaga D; Compañón I; Somovilla VJ; Salvadó M; Asensio JL; Jiménez-Barbero J; Avenoza A; Busto JH; Bernardes GJ; Peregrina JM; Hurtado-Guerrero R; Corzana F
Angew Chem Int Ed Engl; 2015 Aug; 54(34):9830-4. PubMed ID: 26118689
[TBL] [Abstract][Full Text] [Related]
53. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine.
Qi W; Schultes BC; Liu D; Kuzma M; Decker W; Madiyalakan R
Hybrid Hybridomics; 2001; 20(5-6):313-24. PubMed ID: 11839249
[TBL] [Abstract][Full Text] [Related]
54. Epitope characterization of MUC1 antibodies.
Blockzjil A; Nilsson K; Nilsson O
Tumour Biol; 1998; 19 Suppl 1():46-56. PubMed ID: 9422088
[TBL] [Abstract][Full Text] [Related]
55. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
[TBL] [Abstract][Full Text] [Related]
56. Convergent Solid-Phase Synthesis of Macromolecular MUC1 Models Truly Mimicking Serum Glycoprotein Biomarkers of Interstitial Lung Diseases.
Ohyabu N; Kakiya K; Yokoi Y; Hinou H; Nishimura S
J Am Chem Soc; 2016 Jul; 138(27):8392-5. PubMed ID: 27340743
[TBL] [Abstract][Full Text] [Related]
57. Characterization of a panel of monoclonal antibodies using GalNAc glycosylated peptides and recombinant MUC1.
Reis CA; Hassan H; Bennett EP; Clausen H
Tumour Biol; 1998; 19 Suppl 1():127-33. PubMed ID: 9422098
[TBL] [Abstract][Full Text] [Related]
58. Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen.
Schuman J; Campbell AP; Koganty RR; Longenecker BM
J Pept Res; 2003 Mar; 61(3):91-108. PubMed ID: 12558945
[TBL] [Abstract][Full Text] [Related]
59. Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).
Steentoft C; Schjoldager KT; Cló E; Mandel U; Levery SB; Pedersen JW; Jensen K; Blixt O; Clausen H
Glycoconj J; 2010 Aug; 27(6):571-82. PubMed ID: 20721622
[TBL] [Abstract][Full Text] [Related]
60. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
